Replies to post #211868 on Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

If you are correct, why doesn't the market know any of this? Moreover, why are the only folks "in the know" widely scattered chat board regulars?

[To infinity and beyond!]

I get it I get it The drug is just supposed to modulate p53. Like in a petri dish, or something, or maybe in a person.

But does it have to do any more than that?

Gee I wonder why they even have to do anything else at all, i mean, the IP job is all done right?

Never mind if it has to show any benefit to anyone -

silly nit-picking logic, and I am supposed to respond? Ha! Haha!

[BooDog]

Once BP gets all the data and $IPIX and partner set the stage for the next trial, we'll only start to unlock the potential.

[CallMeCrazy]

The essence of FUD.

Your statement... demonstrates a clear [and deliberate] misunderstanding of what Kevetrin [Brilacidin & Prurisol] is supposed to do, actually does and it’s value to a BP.

Message in reply to:

No I’m not wrong. I said it wasn’t a primary outcome. The primary outcome for the study was further understanding pharmacodynamics and MOA. From the beginning of preclinical safety testing, Kevetrin was not meant to be a stand-alone drug, though there was hope it might arrest or reduce tumors on its own without further intervention, especially for those patients having already exhausted all options. Kevetrin efficacy has always been, and continues to be, p53 modulation. Kevetrin clearly is efficacious. Your statement that it has no efficacy demonstrates a clear misunderstanding of what Kevetrin is supposed to do, actually does and it’s value to a BP. (Emphasis added)